Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin-Reference-Cited by-同舟云学术

Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

Published:2020-09-08 Issue:10 Volume:36 Page:1619-1626
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Chien Ching-Lun¹,Chen Yen-Chou²,Malone Daniel C.³,Peng Yueh-Lung⁴,Ko Yu¹⁵

Affiliation:

1. Department of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

2. Division of Cardiovascular Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

3. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

4. Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan

5. Research Center for Pharmacoeconomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

Funder

Center for Drug Evaluation, Taiwan

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1815686

Reference49 articles.

1. Department of Statistics-Ministry of Health and Welfare. 2016 National Health Insurance Annual Statistical. 2017 [cited 2019 June 1]. Available from: https://dep.mohw.gov.tw/DOS/np-3717-113.html

2. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018

3. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review;Advances in Therapy;2023-07-29

2. A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus;PharmacoEconomics;2023-07-06

3. ADA–EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes in an Afro-Asian Context: Broadening the Perspective;European Endocrinology;2023